Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

Journal of Clinical Oncology

Volumn 29, Issue 19, 2011, Pages 2660-2666

  Kurzrock, Razelle ^{a,b,c,d,e,f,g}   Sherman, Steven I ^{a,b,c,d,e,f,g}   Ball, Douglas W ^{a,b,c,d,e,f,g}   Forastiere, Arlene A ^{a,b,c,d,e,f,g}   Cohen, Roger B ^{a,b,c,d,e,f,g}   Mehra, Ranee ^{a,b,c,d,e,f,g}   Pfister, David G ^{a,b,c,d,e,f,g}   Cohen, Ezra E W ^{a,b,c,d,e,f,g}   Janisch, Linda ^{a,b,c,d,e,f,g}   Nauling, Forlisa ^{a,b,c,d,e,f,g}   Hong, David S ^{a,b,c,d,e,f,g}   Ng, Chaan S ^{a,b,c,d,e,f,g}   Ye, Lei ^{a,b,c,d,e,f,g}   Gagel, Robert F ^{a,b,c,d,e,f,g}   Frye, John ^{a,b,c,d,e,f,g}   Müller, Thomas ^{a,b,c,d,e,f,g}   Ratain, Mark J ^{a,b,c,d,e,f,g}   Salgia, Ravi ^{a,b,c,d,e,f,g}  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^g EXELIXIS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; ERYTHROPOIETIN; MOTESANIB; PLACENTAL GROWTH FACTOR; PROTEIN RET; SCATTER FACTOR RECEPTOR; SORAFENIB; VANDETANIB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; XL 184;

ADENOID CYSTIC CARCINOMA; ADULT; AGED; AMYLASE BLOOD LEVEL; ANGIOSARCOMA; AREA UNDER THE CURVE; BODY WEIGHT; CALCITONIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; CARCINOID; CHEMOTHERAPY INDUCED EMESIS; CLEAR CELL SARCOMA; COLORECTAL CANCER; CONFERENCE PAPER; CUTANEOUS T CELL LYMPHOMA; DECREASED APPETITE; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRY SKIN; DYSGEUSIA; FATIGUE; FEMALE; GENE MUTATION; HAIR COLOR; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY CARCINOMA; LIPOSARCOMA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MESOTHELIOMA; MOUTH PAIN; MUCOSA INFLAMMATION; NAUSEA; NEUROENDOCRINE TUMOR; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SARCOMA; SIDE EFFECT; SKIN BIOPSY; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANILIDES; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-RET; PYRIDINES; THYROID NEOPLASMS;

EID: 79959936054     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.4145     Document Type: Conference Paper

References (37)

1. Garcia JA, Rini BI: Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 57:112-125, 2007 (Pubitemid 46535711)
2. Iyer R, Fetterly G, Lugade A, et al: Sorafenib: A clinical and pharmacologic review. Expert Opin Pharmacother 11:1943-1955, 2010
3. Judson I, Demetri G: Advances in the treatment of gastrointestinal stromal tumours. Ann Oncol 18:20-24, 2007 (suppl 10)
4. de Groot JF, Fuller G, Kumar AJ, et al: Tumor invasion after treatment of glioblastoma with bevacizumab: Radiographic and pathologic correlation in humans and mice. Neuro Oncol 12:233-242, 2010
5. Verhoeff JJ, van Tellingen O, Claes A, et al: Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 9:444, 2009
6. Bergers G, Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592-603, 2008
7. Loges S, Mazzone M, Hohensinner P, et al: Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell 15:167-170, 2009
8. Stellrecht CM, Gandhi V: MET receptor tyrosine kinase as a therapeutic anticancer target. Cancer Lett 280:1-14, 2009
9. You WK, McDonald DM: The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep 41:833-839, 2008
10. Joly A: Simultaneous blockade of VEGF and HGF receptors results in potent anti-angiogenic and anti-tumor effects. Eur J Cancer Supplements 4:35-35, 2006
11. Sennino B, Naylor RM, Tabruyn SP, et al: Reduction of tumor invasiveness and metastasis and prolongation of survival of RIP-Tag2 mice after inhibition of VEGFR plus c-Met by XL184. Mol Cancer Ther 8:A13, 2009 (suppl 12)
12. Blaugrund JE, Johns MM Jr, Eby YJ, et al: RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer. Hum Mol Genet 3:1895-1897, 1994
13. Papotti M, Olivero M, Volante M, et al: Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid. Endocr Pathol 11:19-30, 2000 (Pubitemid 30307941)
14. Ivan M, Bond JA, Prat M, et al: Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 14:2417-2423, 1997 (Pubitemid 27268160)
15. Soh EY, Duh QY, Sobhi SA, et al: Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 82:3741-3747, 1997 (Pubitemid 27509365)
16. Tuttle RM, Fleisher M, Francis GL, et al: Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol Metab 87:1737-1742, 2002 (Pubitemid 34615263)
17. Schlumberger M, Carlomagno F, Baudin E, et al: New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab 4:22-32, 2008 (Pubitemid 350291115)
18. Sherman SI: Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 94:1493-1499, 2009
19. Droz JP, Schlumberger M, Rougier P, et al: Chemotherapy in metastatic nonanaplastic thyroid cancer: Experience at the Institut Gustave-Roussy. Tumori 76:480-483, 1990
20. Shimaoka K, Schoenfeld DA, DeWys WD, et al: A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155-2160, 1985 (Pubitemid 16236586)
21. Wells SA, Robinson BG, Gagel RF, et al: Vandetanib in locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial (ZETA). Presented at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010
22. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
23. Cohen EE, Rosen LS, Vokes EE, et al: Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 26:4708-4713, 2008
24. Gupta-Abramson V, Troxel AB, Nellore A, et al: Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719, 2008
25. Robinson BG, Paz-Ares L, Krebs A, et al: Vandetanib (100mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 95:2664-2671, 2010
26. Knowles PP, Murray-Rust J, Kjaer S, et al: Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem 281:33577-33587, 2006 (Pubitemid 46036738)
27. Lam ET, Ringel MD, Kloos RT, et al: Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28:2323-2330, 2010
28. Johanson V, Ahlman H, Bernhardt P, et al: A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis. Endocr Relat Cancer 14:433-444, 2007 (Pubitemid 47242641)
29. Schlumberger MJ, Elisei R, Bastholt L, et al: Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27:3794-3801, 2009
30. Sherman SI, Wirth LJ, Droz JP, et al: Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31-42, 2008 (Pubitemid 351931094)
31. Wells SA Jr, Gosnell JE, Gagel RF, et al: Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an open-label phase II trial. J Clin Oncol 25:303S, 2007 (suppl; abstr 6018)
32. Rini BI, Wilding G, Hudes G, et al: Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27:4462-4468, 2009
33. Goutas N, Vlachodimitropoulos D, Bouka M, et al: BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. Anticancer Res 28:305-308, 2008 (Pubitemid 351362917)
34. Schilling T, Bü rck J, Sinn HP, et al: Prognostic value of codon 918 (ATG3ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer 95:62-66, 2001
35. Tam BY, Wei K, Rudge JS, et al: VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 12:793-800, 2006 (Pubitemid 44050069)
36. Petrelli A, Circosta P, Granziero L, et al: Abinduced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci U S A 103:5090-5095, 2006
37. Akeno-Stuart N, Croyle M, Knauf JA, et al: The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res 67:6956-6964, 2007 (Pubitemid 47105543)